N

Neumora Therapeutics Inc
NASDAQ:NMRA

Watchlist Manager
Neumora Therapeutics Inc
NASDAQ:NMRA
Watchlist
Price: 2.13 USD -0.93% Market Closed
Market Cap: 351m USD

Relative Value

There is not enough data to reliably calculate the relative value of NMRA.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NMRA Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.7
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-5.6
Industry
21.6
Forward
-1.4
vs History
vs Industry
Median 3Y
-8.2
Median 5Y
-8.2
Industry
16.9
vs History
vs Industry
Median 3Y
-8
Median 5Y
-8
Industry
22.9
vs History
60
vs Industry
69
Median 3Y
3.5
Median 5Y
3.5
Industry
2.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.6
vs History
vs Industry
55
Median 3Y
-3.9
Median 5Y
-3.9
Industry
13.4
Forward
-0.8
vs History
vs Industry
52
Median 3Y
-3.9
Median 5Y
-3.9
Industry
16.7
Forward
-0.8
vs History
vs Industry
55
Median 3Y
-6
Median 5Y
-6
Industry
16.1
vs History
vs Industry
41
Median 3Y
-5.9
Median 5Y
-5.9
Industry
18.9
vs History
60
vs Industry
2
Median 3Y
40.6
Median 5Y
40.6
Industry
2

Multiples Across Competitors

NMRA Competitors Multiples
Neumora Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Neumora Therapeutics Inc
NASDAQ:NMRA
344.9m USD 0 -1.5 -0.8 -0.8
US
Eli Lilly and Co
NYSE:LLY
977B USD 16.4 53.1 35.6 38.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
528.3B USD 5.7 21 17.2 22.3
CH
Roche Holding AG
SIX:ROG
275.3B CHF 4.5 29.2 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
217.5B GBP 5 31 108.3 158.5
CH
Novartis AG
SIX:NOVN
219.7B CHF 4.9 19 12 15.5
US
Merck & Co Inc
NYSE:MRK
276B USD 4.3 14.5 10.3 12.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.6 10.9 12.6
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
147.2B USD 2.3 15 7.6 10.4
P/E Multiple
Earnings Growth PEG
US
N
Neumora Therapeutics Inc
NASDAQ:NMRA
Average P/E: 24.8
Negative Multiple: -1.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.1
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
21
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.2
29%
1
UK
AstraZeneca PLC
LSE:AZN
31
37%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.5
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
27%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
N
Neumora Therapeutics Inc
NASDAQ:NMRA
Average EV/EBITDA: 439.9
Negative Multiple: -0.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.6
34%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
17.2
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
12
6%
2
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
N
Neumora Therapeutics Inc
NASDAQ:NMRA
Average EV/EBIT: 1 883.6
Negative Multiple: -0.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.2
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
22.3
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
7%
1.5